Moreover, targeting the Ang II-TGF-β1 pathway by EA treatment could slow down fibrogenic heart disease process and may provide a promising therapeutic approach that could potentially lead to a less invasive and possibly more effective treatment in cardiovascular disorders caused by hypertension-induced myocardial fibrosis. The gene discussed is TGFB1; the disease is Hypertension.